Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Charlotte faith leaders hold interfaith forum on Black and Palestinian solidarity - 2SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- 3'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- 4Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- 5EU waters down plans to end new petrol and diesel car sales by 2035
- The 15 Best Business visionaries Under 40
- Burkina Faso must 'forget' about democracy, military leader says
- A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- Instructions to Warmly greet Discretion and Thoughtfulness
- Spain and Catholic Church agree to compensate sex abuse victims
- Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- Smoking rate among US adults drops to record low as vape use rises, CDC report finds
- Ringleader of suspected human trafficking network arrested in Ethiopia
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
